Your browser doesn't support javascript.
loading
The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
Derington, Catherine G; Bress, Adam P; Herrick, Jennifer S; Fan, Wenjun; Wong, Nathan D; Andrade, Katherine E; Johnson, Jonathan; Philip, Sephy; Abrahamson, David; Jiao, Lixia; Bhatt, Deepak L; Weintraub, William S.
Affiliation
  • Derington CG; Department of Population Health Sciences, University of Utah, School of Medicine, Salt Lake City, UT.
  • Bress AP; Department of Population Health Sciences, University of Utah, School of Medicine, Salt Lake City, UT.
  • Herrick JS; Department of Internal Medicine, University of Utah, School of Medicine, Salt Lake City, UT.
  • Fan W; Department of Internal Medicine, University of Utah, School of Medicine, Salt Lake City, UT.
  • Wong ND; Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, CA.
  • Andrade KE; Heart Disease Prevention Program, Division of Cardiology, University of California Irvine, CA.
  • Johnson J; Optum Insight, Eden Prairie, MN.
  • Philip S; Optum Insight, Eden Prairie, MN.
  • Abrahamson D; Amarin Pharma, Inc., Bridgewater, NJ.
  • Jiao L; Amarin Pharma, Inc., Bridgewater, NJ.
  • Bhatt DL; Amarin Pharma, Inc., Bridgewater, NJ.
  • Weintraub WS; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA.
Am J Prev Cardiol ; 10: 100345, 2022 Jun.
Article in En | MEDLINE | ID: mdl-35574517
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Prev Cardiol Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Prev Cardiol Year: 2022 Document type: Article Country of publication: